临床绒毛膜羊膜炎管理的循证方法
本文综述临床绒毛膜羊膜炎治疗干预的现有证据,以制定循证管理方法。多数抗生素试验纳入孕周≥34周且临产患者。一线方案为产时启动氨苄西林联合庆大霉素,剖宫产时钳夹脐带加用克林霉素,产后通常无需额外抗生素。
要点
- 产时启动氨苄西林联合庆大霉素为一线抗生素方案。
- 剖宫产时钳夹脐带加用克林霉素,产后通常无需额外抗生素。
- 确诊后应考虑分娩,阴道分娩更安全,剖宫产仅限产科指征。
核心结论
- 临床绒毛膜羊膜炎的一线抗生素为产时氨苄西林联合庆大霉素,剖宫产时加用克林霉素。
- 确诊后应考虑分娩,阴道分娩更安全,剖宫产仅限标准产科指征。
- 诊断至分娩时间间隔与多数不良母婴结局无关。
研究设计与样本
- 综述,旨在检查临床绒毛膜羊膜炎治疗干预的现有证据以制定循证管理方法。
- 多数评估抗生素的试验纳入孕周≥34周且临产的患者。
主要发现
- 产时启动氨苄西林联合庆大霉素为一线方案,剖宫产时钳夹脐带加用克林霉素。
- 阴道或剖宫产分娩后额外抗生素治疗似乎不必要;若产后处方抗生素,支持给予额外剂量。
- 可使用退热剂主要是对乙酰氨基酚,虽无明确获益证据。
- 孕24 0/7至33 6/7周及可能23 0/7至23 6/7周使用产前皮质类固醇和硫酸镁对婴儿总体有益,但不应延迟分娩以完成疗程。
- 诊断至分娩时间间隔与多数不良母婴结局无关;患者可能需要更高剂量缩宫素或更大宫缩活性以达到宫颈扩张变化。
关键数值与推荐
- 一线抗生素:氨苄西林联合庆大霉素,产时启动。
- 剖宫产时钳夹脐带给予克林霉素。
- 产前皮质类固醇和硫酸镁用于孕24 0/7至33 6/7周及可能23 0/7至23 6/7周。
- 确诊后应考虑分娩,无论孕周。
- 阴道分娩更安全,剖宫产保留给标准产科指征。
临床怎么用
- 产时启动氨苄西林联合庆大霉素,剖宫产时加用克林霉素。
- 孕24 0/7至33 6/7周及可能23 0/7至23 6/7周使用皮质类固醇和硫酸镁,但不延迟分娩。
- 确诊后考虑分娩,优先阴道分娩,剖宫产仅限产科指征。
- 诊断至分娩时间间隔与多数不良结局无关,无需因间隔延长而干预。
- 持续电子胎心监护的获益不明确。
局限性
- 需要足够把握度的随机对照试验评估有望的干预措施。
- 持续电子胎心监护的获益不明确。
- 退热剂获益无明确证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This review aimed to examine the existing evidence about interventions proposed for the treatment of clinical chorioamnionitis, with the goal of developing an evidence-based contemporary approach for the management of this condition. Most trials that assessed the use of antibiotics in clinical chorioamnionitis included patients with a gestational age of ≥34 weeks and in labor. The first-line antimicrobial regimen for the treatment of clinical chorioamnionitis is ampicillin combined with gentamicin, which should be initiated during the intrapartum period. In the event of a cesarean delivery, patients should receive clindamycin at the time of umbilical cord clamping. The administration of additional antibiotic therapy does not appear to be necessary after vaginal or cesarean delivery. However, if postdelivery antibiotics are prescribed, there is support for the administration of an additional dose. Patients can receive antipyretic agents, mainly acetaminophen, even though there is no clear evidence of their benefits. Current evidence suggests that the administration of antenatal corticosteroids for fetal lung maturation and of magnesium sulfate for fetal neuroprotection to patients with clinical chorioamnionitis between 24 0/7 and 33 6/7 weeks of gestation, and possibly between 23 0/7 and 23 6/7 weeks of gestation, has an overall beneficial effect on the infant. However, delivery should not be delayed to complete the full course of corticosteroids and magnesium sulfate. Once the diagnosis of clinical chorioamnionitis has been established, delivery should be considered, regardless of the gestational age. Vaginal delivery is the safer option and cesarean delivery should be reserved for standard obstetrical indications. The time interval between the diagnosis of clinical chorioamnionitis and delivery is not related to most adverse maternal and neonatal outcomes. Patients may require a higher dose of oxytocin to achieve adequate uterine activity or greater uterine activity to effect a given change in cervical dilation. The benefit of using continuous electronic fetal heart rate monitoring in these patients is unclear. We identified the following promising interventions for the management of clinical chorioamnionitis: (1) an antibiotic regimen including ceftriaxone, clarithromycin, and metronidazole that provides coverage against the most commonly identified microorganisms in patients with clinical chorioamnionitis; (2) vaginal cleansing with antiseptic solutions before cesarean delivery with the aim of decreasing the risk of endometritis and, possibly, postoperative wound infection; and (3) antenatal administration of N-acetylcysteine, an antioxidant and antiinflammatory agent, to reduce neonatal morbidity and mortality. Well-powered randomized controlled trials are needed to assess these interventions in patients with clinical chorioamnionitis.
引用
- Conde-Agudelo A, Romero R, Jung EJ, et al. Management of clinical chorioamnionitis: an evidence-based approach. Am J Obstet Gynecol. 2020. PMID: 33007269. doi:10.1016/j.ajog.2020.09.044
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。